Targets › SLAMF7
10 programs from 9 companies in 11 trials: 5 Phase 2, 4 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.
Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. (UniProt, Q9NQ25)
Open in Phaseline: the race on SLAMF7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| European Myeloma Network B.V. | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 3 | Multiple Myeloma | Mar 2029 |
| Wuerzburg University Hospital | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 3 | Newly Diagnosed Multiple Myeloma | Aug 2029 |
| Massachusetts General Hospital | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 2 | Multiple Myeloma | Dec 2026 |
| Medical College of Wisconsin | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 2 | Multiple Myeloma | Apr 2027 |
| M.D. Anderson Cancer Center | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 2 | Hematopoietic Cell Transplantation Recipient; Myelofibrosis Transformation in Essential Thrombocythemia | Apr 2027 |
| Washington University School of Medicine | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 2 | Multiple Myeloma in Relapse | Sep 2027 |
| Yale University | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 1 | Multiple Myeloma | Dec 2026 |
| Abdullah Khan | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 1 | Recurrent Multiple Myeloma | Dec 2026 |
| Washington University School of Medicine | WS-CART-CS1 SLAMF7-targeting CAR-T cell therapy | SLAMF7 | Phase 1 | Multiple Myeloma | Aug 2029 |
| Omar Nadeem, MD | Elotuzumab SLAM family member 7 inhibitor | SLAMF7 | Phase 1 | Myeloma | Dec 2029 |
Multiple Myeloma (5) Hematopoietic Cell Transplantation Recipient (1) Myelofibrosis Transformation in Essential Thrombocythemia (1) Multiple Myeloma in Relapse (1) Newly Diagnosed Multiple Myeloma (1) Myeloma (1) Recurrent Multiple Myeloma (1)
mixed (8), antibody (1), other (1)
Washington University School of Medicine (2) M.D. Anderson Cancer Center (1) Medical College of Wisconsin (1) Yale University (1) Wuerzburg University Hospital (1) Massachusetts General Hospital (1) Omar Nadeem, MD (1) European Myeloma Network B.V. (1) Abdullah Khan (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.